1 / 29

Drugs for Asthma

Drugs for Asthma . Francesca Burns. Aims and objectives. Understand regulation of airway muscle Pathophysiology of asthma Step-wise management Pharmacology of each drug class Emergency Mx acute asthma attack. Hallmarks of asthma. Intermittent and reversible airway obstruction

mervyn
Download Presentation

Drugs for Asthma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drugs for Asthma Francesca Burns

  2. Aims and objectives • Understand regulation of airway muscle • Pathophysiology of asthma • Step-wise management • Pharmacology of each drug class • Emergency Mx acute asthma attack

  3. Hallmarks of asthma • Intermittent and reversible airway obstruction • Chronic bronchial inflammation with eosinophils • Bronchial smooth muscle cell hypertrophy and hyperractivity • Increased mucus secretion

  4. Regulation of airway muscle, blood vessels and glands Respond to exogenous chemicals, inflammatory mediators and physical stimuli Irritant receptors & C-fibres Afferent pathways Bronchoconstriction and mucus secretion Muscarinic (M3) Parasympathetic Efferent pathways Autonomic innervation β2- adrenoceptors Sympathetic Relax airway smooth muscle Cause neuroinflammation NANC + Cause relaxation -

  5. Pathophysiology: Reversed by β2 adrenoceptor agonists, leukotriene receptor antagonist and theophylline Bronchoconstriction Early phase Increased mucus Vasodilation 2 phases Activation and recruitment of leukocytes Late phase Inflammation Inhibited by glucocorticoids Airway remodelling

  6. Drugs • 2 categories: • Bronchodilators • Anti inflammatory agents

  7. β2 agonist • Mechanism of action: • increase intracellular cAMP leading to smooth muscle relaxation and bronchodilation • Inhibition of mediator release from mast cells • Enhanced mucociliary clearance • Pharmacokinetics: • Administration: inhaler, nebuliser or IV • Short acting: max effect within 30 mins, last 3-5 hours • Long acting: last 8-12 hours • Metabolised by liver

  8. Indications: • Acute asthma (short acting) • Chronic asthma/COPD (long acting) • Premature labour • Cautions: hyperthyroidism, cardiovascular disease, arrhythmias, susceptibility to QT-interval prolongation, and hypertension.

  9. Fine tremor • Hypokalaemia (if high dose given) • Tachycardia – secondary to peripheral vasodilation and cardiac stimulation • Headache • Side effects:

  10. Steroids • Mechanism of action: anti-inflammatory • Decrease formation of cytokines (esp Th2) • Inhibit induction of COX-2 • Pharmacokinetics: • Administration: inhaled or oral • t = variable (12-36 pred, 8-12 hydrocortisone) • Metabolised predominantly in liver

  11. Side effects: • Oropharyngeal candidiasis • Bruising and impaired healing • Osteoporosis • Peptic ulcerations • Increased susceptibility to infections • …….. • Cautions: pregnancy and in growing children

  12. Leukotriene receptor antagonist(e.g.Montelukast, zafirlukast) • Mechanism of action: block action of cysteinylleukotrienes in smooth muscle , therefore inhibiting inflammation • Pharmacokinetics: • Administration: oral (Mx1D, Zx2D) • t=3-7h (montelukast) • Metabolised by liver and excreted by biliary route • Indications: • Asthma (step 3) • Seasonal allergic rhinitis

  13. Cautions: • In patients taking liver inducing drugs • Phenobarbitol use reduces plasma levels • Avoid in P&B unless essential • Side effects: • Abdo pain • GI disturbance • Headache • Churg Strauss

  14. SR TheophyllineA methylxanthine • Mechanism of action: inhibits phosphodiesteraseisoenzymes resulting in increased cAMP levels and smooth muscle relaxation  bronchodilatory effect. • Pharmacokinetics: • Administration: oral • t= 8 hours • Metabolised by liver (CP450) and excreted by kidneys • Indications: • Acute severe asthma • Chronic asthma • Moderate to severe COPD

  15. Cautions: • Porphyria • Concomitant use of ephedrine in children • Cardiac or liver failure and poorly controlled epilepsy • t reduced by smoking, heavy drinking and p450 inducers • Monitor K+ levels • Side effects: • Hypokalaemia • Tachycardia, palpitations, and arrthymias • Headache and insomnia • GI disturbances • Convulsions

  16. Inhaled antimuscarinicsIpatropium bromide • Mechanism action: • competitive agonists of Ach in bronchial smooth muscle. • Bind and block M3 receptors • Therefore prevent smooth muscle contraction and consequent airway constriction • Pharmacokinetics: • Given by aerosol inhalation • Max effect at 30 mins, t 1.6 hours • Excreted in urine

  17. Cautions: prostatic hyperplasia, bladder outflow obstruction, and those susceptible to angle-closure glaucoma • Indications: asthma • Side effects: • Dry mouth • Nausea • Headache

  18. Management of Acute Asthma attackOh – S H I T ! • O - Oxygen • S – Salbutamol (nebuliser, followed by course of oral prednisolone) • H – Hydrocortisone (IV) • I - Ipatropium • T – theophylline (or MgSO4)

  19. Last thing…Aspirin induced asthma • 5% individuals with asthma experience exacerbations when they take aspirin or other NSAIDS. • Samters triad: Asthma, aspirin sensitivity, nasal polyps • Common in middle aged men • This occurs because aspirin is a mixed COX-1 and COX-2 inhibitor, reducing PG2 and increasing leukotriene synthesis…causing bronchospasm. • Prior learning: Ali teach

  20. Questions • 1. A 33-year-old man is seen in the asthma clinic. He was referred with poorly control asthma and has recently had salmeterol added in addition to beclometasonedipropionate inhaler 200mcg bd and salbutamol prn. There has unfortunately been no response to adding the salmeterol. What is the most appropriate action? • Stop salmetarol and trial of leukotriene receptor antagonist • Continue salmeterol + increase beclometasonedipropionate inhaler to 400mcg bd • Continue salmeterol + trial of leukotriene receptor antagonist • Stop salmeterol + trial of oral theophylline • Stop salmeterol + increase beclometasonedipropionate inhaler to 400mcg bd

  21. A 45-year-old woman who is a known asthmatic comes for review. In the past two years she has had around six exacerbations of asthma requiring oral steroids. Her current medication includes salbutamol 2 puffs prn, salmeterol 50mcg bd and beclomethasone 200 mcg 1 puff bd. You note from the records that her BMI is 31 kg/m^2, she is a non-smoker and has a good inhaler technique. What is the most appropriate next step in management? • Increase beclomethasone to 200 mcg 2 puffs bd • Referral to a dietician • Add oral theophylline • Add oral montelukast • Add inhaled tiopropium

  22. Which of the following are common adverse effects of B2 agonists? • A) Tremor • B)Bradycardia • C) Ankle oedema • D)Tachycardia • E)Oral Candidiasis

More Related